Home > Oncology > ASCO 2022 > Gynaecological Cancers > Encouraging results of relacorilant in ovarian cancer

Encouraging results of relacorilant in ovarian cancer

Presented By
Prof. Nicoletta Colombo, University of Milan, Italy
Conference
ASCO 2022
Doi
https://doi.org/10.55788/09959e75
The glucocorticoid receptor modulator relacorilant added to nab-paclitaxel demonstrated an overall survival (OS) benefit over nab-paclitaxel alone in patients with platinum-resistant/refractory ovarian cancer. These results provide evidence that cortisol modulation is a promising novel modality in oncology. A phase 2 study randomised 178 patients with recurrent platinum-resistant ovarian cancer to intermittent relacorilant plus nab-paclitaxel, continuous relacorilant plus nab-paclitaxel, or nab-paclitaxel alone. The primary analysis showed a significantly improved median progression-free survival (PFS) for patients in the intermittent arm compared with the nab-paclitaxel alone arm (5.55 vs 3.76 months; HR 0.66; log-rank P=0.038). Prof. Nicoletta Colombo (University of Milan, Italy) presented the final results of the study, including mature OS results [1]. The updated PFS rates were similar with those of the primary analysis, with a median ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on